Stemline Therapeutics
As of the edition of 20 October 2026, Stemline Therapeutics runs 9 drugs, 4 of them marketed; it is on route A at 1 target and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
- Stemline Therapeutics, Inc.: acquired in 2020; successor Berlin-Chemie AG
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Selinexor | Ends 2035 (patent) | 2 |
| Edoxaban | Ends 2027 (patent) | 1 |
| Elacestrant | Ends 2038 (patent) | 1 |
| Tagraxofusp | Ends 2030 (computed from the first US licence) | 4 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 4 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Stemline Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 13 trials led
- Skin and connective tissue: 9 trials led
- Blood and lymph: 4 trials led